JP2012508215A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508215A5
JP2012508215A5 JP2011535129A JP2011535129A JP2012508215A5 JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5 JP 2011535129 A JP2011535129 A JP 2011535129A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5
Authority
JP
Japan
Prior art keywords
salt
salt according
optionally
degrees
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011535129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064889 external-priority patent/WO2010055027A2/en
Publication of JP2012508215A publication Critical patent/JP2012508215A/ja
Publication of JP2012508215A5 publication Critical patent/JP2012508215A5/ja
Withdrawn legal-status Critical Current

Links

JP2011535129A 2008-11-11 2009-11-10 有機化合物 Withdrawn JP2012508215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168862.4 2008-11-11
EP08168862 2008-11-11
PCT/EP2009/064889 WO2010055027A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015089480A Division JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Publications (2)

Publication Number Publication Date
JP2012508215A JP2012508215A (ja) 2012-04-05
JP2012508215A5 true JP2012508215A5 (enExample) 2012-12-20

Family

ID=42062355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011535129A Withdrawn JP2012508215A (ja) 2008-11-11 2009-11-10 有機化合物
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Country Status (20)

Country Link
US (2) US8680146B2 (enExample)
EP (1) EP2358660A2 (enExample)
JP (2) JP2012508215A (enExample)
KR (1) KR20110086142A (enExample)
CN (2) CN105198760A (enExample)
AU (1) AU2009315735B2 (enExample)
BR (1) BRPI0921533A2 (enExample)
CA (1) CA2741974A1 (enExample)
CL (1) CL2011001041A1 (enExample)
CO (1) CO6382154A2 (enExample)
EC (1) ECSP11011121A (enExample)
IL (1) IL212073A0 (enExample)
MA (1) MA32877B1 (enExample)
MX (1) MX2011004924A (enExample)
NZ (1) NZ591999A (enExample)
PE (1) PE20120012A1 (enExample)
RU (1) RU2543621C2 (enExample)
TN (1) TN2011000187A1 (enExample)
WO (1) WO2010055027A2 (enExample)
ZA (1) ZA201102272B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
PE20120012A1 (es) * 2008-11-11 2012-02-02 Novartis Ag Sales de fingolimod
KR20120032538A (ko) * 2009-07-24 2012-04-05 라티오팜 게엠베하 핀골리모드 염의 제조 방법
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
MX2013004649A (es) 2010-10-28 2013-06-05 Mapi Pharma Ltd Compuestos intermedios y proceso para la preparacion de fingolimod.
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP6484567B2 (ja) 2013-03-05 2019-03-13 バイオコン・リミテッドBiocon Limited 2−アミノ−1,3−プロパンジオール化合物およびその塩の製造のための方法
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CN109563057B (zh) 2016-05-31 2022-06-24 大鹏药品工业株式会社 磺酰胺化合物或其盐
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
TWI762743B (zh) 2017-11-29 2022-05-01 日商大鵬藥品工業股份有限公司 磺醯胺化合物及其用途
KR20210025615A (ko) * 2018-06-29 2021-03-09 포르마 세라퓨틱스 인크. (s)-(5-시클로부톡시-2-메틸-6-(1-(피페리딘-4-일)-1h-피라졸-4-일)-3,4-디히드로퀴놀린-1(2h)-일)(시클로프로필)메타논의 염 및 그의 고체 형태
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
EP1457478B1 (en) * 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
PL372103A1 (en) * 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
NZ592339A (en) 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
EP1940388A2 (en) * 2005-09-30 2008-07-09 Novartis AG Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection
US8318812B2 (en) * 2006-06-02 2012-11-27 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
US7985586B2 (en) * 2008-02-04 2011-07-26 Georgia Health Sciences University Oligodendrocyte precursor cell composition and methods of use
PE20120012A1 (es) * 2008-11-11 2012-02-02 Novartis Ag Sales de fingolimod

Similar Documents

Publication Publication Date Title
JP2012508215A5 (enExample)
RU2011123365A (ru) Соли финголимода
RU2011123371A (ru) Кристаллические формы гидрохлорида финголимода
ES2683355T3 (es) Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
JP2018035160A5 (enExample)
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
JP2010514829A5 (enExample)
ME02275B (me) Polimorfni oblik rotigotina
JP2010518061A5 (enExample)
RU2013107748A (ru) Производные с-арилглюкозидов, способ их получения и фармацевтическое применение
JP2012523395A5 (enExample)
JP2009084270A5 (enExample)
JP2017527578A5 (enExample)
JP2018518537A5 (enExample)
JP2011510014A5 (enExample)
JP2010514831A5 (enExample)
RU2011145054A (ru) Кристаллические формы саксаглиптина
JP2015145426A5 (enExample)
JP2010514832A5 (enExample)
JP2014511892A5 (enExample)
JP2014524442A5 (enExample)
JP2010529203A5 (enExample)
JP2011516477A5 (enExample)
JP2020510661A5 (enExample)
JP2016503010A5 (enExample)